Document Detail


Drug-induced acute pancreatitis: an evidence-based review.
MedLine Citation:
PMID:  17395548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The diagnosis of drug-induced acute pancreatitis often is difficult to establish. Although some medications have been shown to cause acute pancreatitis with a large body of evidence, including rechallenge, some medications have been attributed as a cause of acute pancreatitis merely by a single published case report in which the investigators found no other cause. In addition, some medications reported to have caused acute pancreatitis have obvious patterns of presentation, including the time from initiation to the development of disease (latency). There also appear to be patterns in the severity of disease. After reviewing the literature, we have classified drugs that have been reported to cause acute pancreatitis based on the published weight of evidence for each agent and the pattern of clinical presentation. Based on our analysis of the level of evidence, 4 classes of drugs could be identified. Class I drugs include medications in which at least 1 case report described a recurrence of acute pancreatitis with a rechallenge with the drug. Class II drugs include drugs in which there is a consistent latency in 75% or more of the reported cases. Class III drugs include drugs that had 2 or more case reports published, but neither a rechallenge nor a consistent latency period. Class IV drugs were similar to class III drugs, but only 1 case report had been published. Our analysis allows an evidence-based approach when suspecting a drug as causing acute pancreatitis.
Authors:
Nison Badalov; Robin Baradarian; Kadirawel Iswara; Jianjun Li; William Steinberg; Scott Tenner
Related Documents :
17418528 - Pharmacogenomics and its implications for autoimmune disease.
15568118 - Adverse drug reactions in singaporean children.
11126698 - Post-release drug treatment risks: strategies to minimise harm to patients.
9825948 - Post-marketing studies: the work of the drug safety research unit.
20555388 - Drug resistance is affected by colocalization of p-glycoproteins in raft-like structure...
20653678 - Prevalence of potentially hazardous drug interactions amongst australian veterans.
Publication Detail:
Type:  Journal Article; Review     Date:  2007-03-28
Journal Detail:
Title:  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association     Volume:  5     ISSN:  1542-7714     ISO Abbreviation:  Clin. Gastroenterol. Hepatol.     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-04     Completed Date:  2007-11-30     Revised Date:  2008-01-17    
Medline Journal Info:
Nlm Unique ID:  101160775     Medline TA:  Clin Gastroenterol Hepatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  648-61; quiz 644     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology, Maimonides Medical Center, Mount Sinai School of Medicine, Brooklyn, New York 11235, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Pancreatitis / chemically induced*
Tetracycline / adverse effects
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 60-54-8/Tetracycline
Comments/Corrections
Comment In:
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1493; author reply 1494   [PMID:  17919991 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell...
Next Document:  Factors associated with early study discontinuation in AACTG studies, DACS 200.